Kreimeier U, Messmer K
Institut für Anaesthesiologie, Ludwig-Maximilians-Universität München.
Anaesthesist. 1996 Oct;45(10):884-99. doi: 10.1007/s001010050322.
Trauma and associated major blood losses in Germany represent the leading cause of mortality in patients up to 45 years of age. The endpoints of prehospital fluid resuscitation in traumatic-hemorrhagic shock are the restitution of intravascular volume und cardiac preload, in order to increase cardiac output and thus provide adequate oxygen delivery to the tissues. The key therapeutic factor to prevent the development of multiple organ failure complicating trauma and shock, however, is the normalization not only of macrohemodynamics (systemic blood pressure. cardiac output), but the restitution of the disturbed microvascular perfusion. In case of major blood loss and exsanguination this can not be achieved by crystalloids and synthetic colloids used in conventional volume therapy. A new concept consists of i.v. bolus infusion of a small volume (4 ml/kg body weight) of a hyperosmolar (7.2-7.5%) NaCl/colloid solution, which is termed "Small-volume Resuscitation". Recently presented data from a cohort analysis of 8 preclinical studies show an increase in survival rate by about 5% when compared to standard of care. In addition, artificial oxygen carrying solutions are currently investigated. by which-through an increase of O2-blood content-oxygen delivery to the tissues might be augmented.
在德国,创伤及相关的大量失血是45岁以下患者死亡的主要原因。创伤性失血性休克的院前液体复苏终点是恢复血管内容量和心脏前负荷,以增加心输出量,从而为组织提供充足的氧输送。然而,预防创伤和休克并发多器官功能衰竭的关键治疗因素不仅是宏观血流动力学(全身血压、心输出量)的正常化,还包括恢复紊乱的微血管灌注。在大量失血和失血过多的情况下,传统容量治疗中使用的晶体液和合成胶体无法实现这一点。一个新的概念是静脉推注小剂量(4毫升/千克体重)高渗(7.2 - 7.5%)氯化钠/胶体溶液,这被称为“小容量复苏”。最近一项对8项临床前研究的队列分析数据显示,与标准治疗相比,生存率提高了约5%。此外,目前正在研究人工携氧溶液,通过增加血液中的氧含量,可能会增加向组织的氧输送。